ClinicalTrials.gov
public full text
Public Domain
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer#1173382
- Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer#982374
- Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage#923020
- Dasatinib in Advanced Squamous Cell Lung Cancer#995243
- Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer#834847
Record · ID 1094937
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive